drugset / Trial / NCT05478993
Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, multicenter, exploratory study initiated by investigator to evaluate the efficacy and safety of Selinexor (S) combined with pomalidomide (P) and dexamethasone (D) in the treatment of multiple myeloma with CNS involvement.
Timeline
- Start
- 2022-10-12
- Primary completion
- 2024-07-10
- Completion
- 2025-07-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 40 mg | — |
| Subject | Pomalidomide | Other / unclassified | 4 mg | — |
| Subject | Selinexor | Other / unclassified | 20 mg | Oral |
| Subject | Selinexor | Other / unclassified | 60 mg | Oral |